Bcl2 is the guardian of microtubule integrity

• Published in: Cancer research (Chicago, Ill.) Vol. 57; no. 2; pp. 229 - 233
• Main Authors: HALDAR, S, BASU, A, CROCE, C. M
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 15.01.1997
• Subjects: Antineoplastic agents; Antineoplastic Agents - pharmacology; Antineoplastic Agents, Phytogenic - pharmacology; Apoptosis - drug effects; Biological and medical sciences; Chronic Disease; G2 Phase; General aspects; Humans; Leukemia - metabolism; Leukemia - pathology; Lymphoma, B-Cell - drug therapy; Lymphoma, B-Cell - metabolism; Male; Medical sciences; Microtubules - drug effects; Paclitaxel - analogs & derivatives; Paclitaxel - pharmacology; Pharmacology. Drug treatments; Phosphorylation; Prostatic Neoplasms - drug therapy; Prostatic Neoplasms - metabolism; Proto-Oncogene Proteins c-bcl-2 - drug effects; Proto-Oncogene Proteins c-bcl-2 - metabolism; Proto-Oncogene Proteins c-bcl-2 - physiology; Taxoids; Tumor Cells, Cultured - drug effects; Antineoplastic agent; Human; Phosphorylation; Taxol; Docetaxel; In vitro; Cell death; C-Onc gene; Taxane derivatives; Established cell line; Microtubule; Mechanism of action; Tumor cell; Apoptosis

We have investigated the ability of several drugs commonly used in the treatment of human cancer to induce bcl2 phosphorylation and cell death in human cell lines derived from acute leukemia, lymphoma, breast cancer, and prostate cancer. The results of this analysis indicate that drugs affecting the...